vs
Side-by-side financial comparison of Doximity, Inc. (DOCS) and DYNAVAX TECHNOLOGIES CORP (DVAX). Click either name above to swap in a different company.
Doximity, Inc. is the larger business by last-quarter revenue ($185.1M vs $94.9M, roughly 2.0× DYNAVAX TECHNOLOGIES CORP). Doximity, Inc. runs the higher net margin — 33.3% vs 28.4%, a 4.9% gap on every dollar of revenue. On growth, DYNAVAX TECHNOLOGIES CORP posted the faster year-over-year revenue change (17.7% vs 9.8%). Over the past eight quarters, DYNAVAX TECHNOLOGIES CORP's revenue compounded faster (30.6% CAGR vs 25.2%).
Doximity is an online networking service for medical professionals. Launched in 2010, the platform offers its members curated medical news, telehealth tools, and case collaboration.
Dynavax Technologies Corp is a commercial-stage biopharmaceutical company specializing in the research, development, and production of innovative vaccines and immunotherapies for infectious diseases. Its lead approved product is Heplisav-B, an adult hepatitis B vaccine, with core markets in North America and Europe, alongside a pipeline of candidates addressing unmet public health needs.
DOCS vs DVAX — Head-to-Head
Income Statement — Q3 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $185.1M | $94.9M |
| Net Profit | $61.6M | $26.9M |
| Gross Margin | 89.9% | — |
| Operating Margin | 38.9% | 22.4% |
| Net Margin | 33.3% | 28.4% |
| Revenue YoY | 9.8% | 17.7% |
| Net Profit YoY | -18.1% | 53.0% |
| EPS (diluted) | $0.31 | $0.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $185.1M | — | ||
| Q3 25 | $168.5M | $94.9M | ||
| Q2 25 | $145.9M | $95.4M | ||
| Q1 25 | $138.3M | $68.2M | ||
| Q4 24 | $168.6M | $72.0M | ||
| Q3 24 | $136.8M | $80.6M | ||
| Q2 24 | $126.7M | $73.8M | ||
| Q1 24 | $118.1M | $50.8M |
| Q4 25 | $61.6M | — | ||
| Q3 25 | $62.1M | $26.9M | ||
| Q2 25 | $53.3M | $18.7M | ||
| Q1 25 | $62.5M | $-96.1M | ||
| Q4 24 | $75.2M | $7.0M | ||
| Q3 24 | $44.2M | $17.6M | ||
| Q2 24 | $41.4M | $11.4M | ||
| Q1 24 | $40.6M | $-8.7M |
| Q4 25 | 89.9% | — | ||
| Q3 25 | 90.3% | — | ||
| Q2 25 | 89.2% | — | ||
| Q1 25 | 89.5% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 90.0% | — | ||
| Q2 24 | 89.3% | — | ||
| Q1 24 | 89.4% | — |
| Q4 25 | 38.9% | — | ||
| Q3 25 | 37.8% | 22.4% | ||
| Q2 25 | 37.4% | 15.1% | ||
| Q1 25 | 35.2% | -34.7% | ||
| Q4 24 | 47.4% | -2.3% | ||
| Q3 24 | 38.8% | 12.5% | ||
| Q2 24 | 36.4% | 7.0% | ||
| Q1 24 | 35.5% | -35.0% |
| Q4 25 | 33.3% | — | ||
| Q3 25 | 36.8% | 28.4% | ||
| Q2 25 | 36.5% | 19.6% | ||
| Q1 25 | 45.2% | -141.0% | ||
| Q4 24 | 44.6% | 9.8% | ||
| Q3 24 | 32.3% | 21.8% | ||
| Q2 24 | 32.7% | 15.4% | ||
| Q1 24 | 34.4% | -17.2% |
| Q4 25 | $0.31 | — | ||
| Q3 25 | $0.31 | $0.21 | ||
| Q2 25 | $0.27 | $0.14 | ||
| Q1 25 | $0.31 | $-0.77 | ||
| Q4 24 | $0.37 | $0.07 | ||
| Q3 24 | $0.22 | $0.12 | ||
| Q2 24 | $0.21 | $0.08 | ||
| Q1 24 | $0.20 | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $64.8M | $160.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $979.3M | $534.1M |
| Total Assets | $1.2B | $946.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $64.8M | — | ||
| Q3 25 | $169.2M | $160.2M | ||
| Q2 25 | $137.3M | $99.1M | ||
| Q1 25 | $209.6M | $51.7M | ||
| Q4 24 | $165.3M | $95.9M | ||
| Q3 24 | $184.2M | $119.3M | ||
| Q2 24 | $111.4M | $112.5M | ||
| Q1 24 | $96.8M | $132.0M |
| Q4 25 | $979.3M | — | ||
| Q3 25 | $1.1B | $534.1M | ||
| Q2 25 | $1.0B | $494.2M | ||
| Q1 25 | $1.1B | $530.9M | ||
| Q4 24 | $1.0B | $596.8M | ||
| Q3 24 | $961.2M | $681.4M | ||
| Q2 24 | $913.6M | $642.8M | ||
| Q1 24 | $901.4M | $618.5M |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.3B | $946.5M | ||
| Q2 25 | $1.2B | $918.4M | ||
| Q1 25 | $1.3B | $945.9M | ||
| Q4 24 | $1.2B | $986.3M | ||
| Q3 24 | $1.1B | $1.1B | ||
| Q2 24 | $1.1B | $1.0B | ||
| Q1 24 | $1.1B | $986.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $60.9M | $33.8M |
| Free Cash FlowOCF − Capex | — | $32.6M |
| FCF MarginFCF / Revenue | — | 34.4% |
| Capex IntensityCapex / Revenue | — | 1.3% |
| Cash ConversionOCF / Net Profit | 0.99× | 1.26× |
| TTM Free Cash FlowTrailing 4 quarters | — | $80.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $60.9M | — | ||
| Q3 25 | $93.9M | $33.8M | ||
| Q2 25 | $62.1M | $23.4M | ||
| Q1 25 | $98.5M | $-19.6M | ||
| Q4 24 | $65.2M | $53.0M | ||
| Q3 24 | $68.3M | $19.5M | ||
| Q2 24 | $41.2M | $10.7M | ||
| Q1 24 | $63.9M | $-16.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | $32.6M | ||
| Q2 25 | — | $22.0M | ||
| Q1 25 | — | $-23.6M | ||
| Q4 24 | — | $49.5M | ||
| Q3 24 | — | $18.1M | ||
| Q2 24 | — | $9.9M | ||
| Q1 24 | — | $-17.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | 34.4% | ||
| Q2 25 | — | 23.0% | ||
| Q1 25 | — | -34.6% | ||
| Q4 24 | — | 68.8% | ||
| Q3 24 | — | 22.5% | ||
| Q2 24 | — | 13.5% | ||
| Q1 24 | — | -34.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | 0.0% | 5.8% | ||
| Q4 24 | 0.0% | 4.8% | ||
| Q3 24 | 0.0% | 1.7% | ||
| Q2 24 | 0.0% | 1.1% | ||
| Q1 24 | 0.0% | 1.5% |
| Q4 25 | 0.99× | — | ||
| Q3 25 | 1.51× | 1.26× | ||
| Q2 25 | 1.16× | 1.25× | ||
| Q1 25 | 1.58× | — | ||
| Q4 24 | 0.87× | 7.52× | ||
| Q3 24 | 1.55× | 1.11× | ||
| Q2 24 | 1.00× | 0.94× | ||
| Q1 24 | 1.57× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOCS
| Subscription | $175.4M | 95% |
| Service Other | $9.7M | 5% |
DVAX
| HEPLISAVB | $90.0M | 95% |
| US Department Of Defense | $4.7M | 5% |
